Nuvation Bio Inc. Class A (NUVB)

Name: Nuvation Bio Inc. Class A (NUVB) Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: Nuvation Bio Inc. Class A (NUVB)

Stock Card

$6.67

$0.01 (0.15%)

As on 31-Aug-2026 16:00EDT

Market cap

$2,398 Mln

Revenue (TTM)

$170 Mln

P/E Ratio

P/B Ratio

Div. Yield

0 %

Nuvation Bio Inc. Class A (NUVB) Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 6.49 High: 6.75

52 Week Range

Low: 2.91 High: 9.75

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$0 Mln
ROE

-0.5 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

2.2
Debt to Equity

1
Book Value

$--
EPS

$-0.4
Face value

--
Shares outstanding

350,123,233

6 Years Aggregate

CFO

$-269.47 Mln

EBITDA

$-369.28 Mln

Net Profit

$-283.73 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
Nuvation Bio Inc. Class A (NUVB)	-25.6	-0.4	39.5	124.6	59.3	-6.7	--
BSE Sensex^*	-9.1	-1.5	2.9	-3.6	5.9	6.0	10.5
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 31-Aug-2026 | *As on 01-Sep-2026 | #As on 26-Oct-2023

Company	2025	2024	2023	2022	2021
Nuvation Bio Inc. Class A (NUVB)	236.8	75.3	-21.4	-77.4	-27.4
S&P Small-Cap 600	4.0	7.0	13.9	-17.4	25.3
BSE Sensex	9.1	8.1	18.7	4.4	22.0

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Peers

View Details

Company	Price ($)	Market Cap ($ Mln)	Revenue (TTM)	Net Profit (TTM)	OPM (%)	ROE (%)	P/E	P/B
Nuvation Bio Inc. Class A (NUVB)	6.7	2,398.2	169.9	-149.8	-76.0	-53.5	--	10.0
Arrowhead Pharmaceuticals (ARWR)	82.4	11,993.9	669.5	-320.0	-0.8	-71.1	--	26.9
Cytokinetics Inc (CYTK)	70.9	10,022.2	71.0	-894.0	-1,175.8	--	--	60.3
Exelixis (EXEL)	54.6	13,491.7	2,435.9	860.6	31.0	43	17.4	7.4
Halozyme Therapeutics (HALO)	106.5	11,957.0	1,663.7	413.6	36.3	430	30.9	84.5
Krystal Biotech (KRYS)	359.4	10,402.8	440.5	241.5	33.4	18.7	44.1	7.8
Madrigal Pharmaceuticals (MDGL)	540.0	12,332.1	1,283.9	-325.1	-19.0	-57.7	--	24.0
Medpace Holdings (MEDP)	594.0	16,765.1	2,782.3	491.5	21.1	110.1	35.2	39.3
Praxis Precision MedicinesÂ Inc (PRAX)	350.3	9,625.4	0.0	-339.1	--	-30.6	--	7.6
Protagonist Therapeutics (PTGX)	147.8	9,339.4	282.0	82.9	-28.6	11.4	140.1	11.5

Shareholding Pattern

View Details

About Nuvation Bio Inc. Class A (NUVB)

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on developing product candidates for cancer treatment. The company's lead product candidate is IBTROZI (taletrectinib), a ROS1 inhibitor for the treatment of patients with ROS1+... non-small cell lung cancer. It is also developing Safusidenib, an inhibitor of mutant isocitrate dehydrogenase 1 in phase 3 clinical trials for the maintenance treatment of high-risk or high-grade IDH1-mutant astrocytoma with safusidenib against placebo. The company was founded in 2018 and is headquartered in New York, New York. Read more

Founder, President, CEO & Director

Dr. David T. Hung M.D.
Chief Scientific Officer

Dr. Gary Hattersley Ph.D.
Headquarters

New York, NY
Website

https://www.nuvationbio.com

FAQs for Nuvation Bio Inc. Class A (NUVB)

What is the current share price of Nuvation Bio Inc Class A (NUVB) Today?

The share price of Nuvation Bio Inc Class A (NUVB) is $6.67 (NYSE) as of 31-Aug-2026 16:00 EDT. Nuvation Bio Inc Class A (NUVB) has given a return of 59.3% in the last 3 years.

What is the current PB & PE ratio of Nuvation Bio Inc Class A (NUVB)?

Since, TTM earnings of Nuvation Bio Inc Class A (NUVB) is negative, P/E ratio is not available.
The P/B ratio of Nuvation Bio Inc Class A (NUVB) is 10.04 times as on 21-Aug-2026, a 94 premium to its peers’ median range of 5.18 times.

PE & PB ratio at the end of financial year.

Year	P/E Ratio	P/B Ratio
2025	-15.08	10.09
2024	-1.58	1.93
2023	-4.36	0.55
2022	-4.03	0.64
2021	-19.82	2.31

What is the 52 Week High and Low of Nuvation Bio Inc Class A (NUVB)?

The 52-week high and low of Nuvation Bio Inc Class A (NUVB) are Rs 9.75 and Rs 2.91 as of 01-Sep-2026.

What is the market cap of Nuvation Bio Inc Class A (NUVB)?

Nuvation Bio Inc Class A (NUVB) has a market capitalisation of $ 2,398 Mln as on 21-Aug-2026. As per SEBI classification, it is a Small Cap company.

Should I invest in Nuvation Bio Inc Class A (NUVB)?

Before investing in Nuvation Bio Inc Class A (NUVB), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.

For guidance, explore our expert-curated portfolios and Stock recommendations with Value Research Stock Advisor.

Want to explore on your own? Click here to see how this stock scores on quality, growth, valuation, and momentum.